CA
CASI Pharmaceuticals, Inc.
CASI · NASDAQ
$0.15 +3.08% (+$0.00)
Market Cap $2.25M
P/E Ratio -
Div. Yield -
ROE 358.32%
Piotroski F-Score Weak
3/9Valuation
100 /100
Cheap P/S 0.08x
P/E N/A
EV/EBITDA N/A
Growth
78 /100
Growing Rev. growth 118.52%
Book val. growth 15.16%
EPS growth N/A
Profitability
16 /100
Weak Gross margin 35.80%
Net margin 183.93%
Op. margin 167.98%
Quality
44 /100
Average ROIC 1,210.78%
ROE 358.32%
ROA 201.86%
Debt
50 /100
Moderate Current ratio 0.30x
Int. coverage -31.98x
Net debt/EBITDA -0.34x
Stability
48 /100
Moderate Beta 0.89x
Rev. volatility 116.31%
EPS volatility 25.29%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na CASI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David A. Cory
Employees
233
Headquarters
Beijing